Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Danielle Brazel

Showing results (1-10 of 42) with videos related to

Pageof 5
Sort By:
Translational Lung Cancer Research|July 8, 2024
The APPLE trial in the evolving landscape of ctDNA monitoringDanielle Brazel, Misako Nagasaka
Med (New York, N.Y.)|August 10, 2024
Checkmate 77T: Perioperative chemoimmunotherapy outperforms in early-stage NSCLCDanielle Brazel, Misako Nagasaka
Targeted Oncology|May 13, 2024
Divarasib in the Evolving Landscape of KRAS G12C Inhibitors for NSCLCDanielle Brazel, Misako Nagasaka
Respiratory Research|October 25, 2023
The development of amivantamab for the treatment of non-small cell lung cancerDanielle Brazel, Misako Nagasaka
Cancers|February 13, 2026
Uveal Melanoma: Biology, Prognostication, and Emerging Therapies to Outsmart an Immune-Cold MelanomaDanielle Brazel, Elizabeth Buchbinder
Lung Cancer (Auckland, N.Z.)|December 9, 2021
Spotlight on Amivantamab (JNJ-61186372) for EGFR Exon 20 Insertions Positive Non-Small Cell Lung CancerDanielle Brazel, Misako Nagasaka
Lung Cancer (Auckland, N.Z.)|May 26, 2022
Deconstructing ADAURA. It is Not Yet Time to Forgo Platinum-based Adjuvant Chemotherapy in Resected Early Stage (IB-IIIA) EGFR-mutant NSCLCDanielle Brazel, Misako Nagasaka
Lung Cancer (Auckland, N.Z.)|April 18, 2024
MARIPOSA: Can Amivantamab and Lazertinib Replace Osimertinib in the Front-Line Setting?Danielle Brazel, Misako Nagasaka
Clinical Lymphoma, Myeloma & Leukemia|April 15, 2023
SOHO State-of-the-Art Updates and Next Questions: A Modern Approach to the Systemic Treatment of Advanced CTCLDanielle Brazel, Lauren Pinter-Brown
Lung Cancer (Auckland, N.Z.)|June 29, 2023
The Additional Exclusions of <i>ROS1</i> Fusions (In Addition to <i>EGFR</i> Mutation and <i>ALK</i> Fusions) in the Cemiplimab NSCLC FDA Indication (EMPOWER-Lung 1 and -Lung 3). Catching Up with Current Scientific View of Immunotherapy in Never-Smoker Predominant Actionable Driver Mutation Positive NSCLC?Danielle Brazel, Saihong Ignatius Ou
Pageof 5

Showing results (1-10 of 42) with videos related to

Sort By:
Pageof 5
Translational Lung Cancer Research|July 8, 2024
The APPLE trial in the evolving landscape of ctDNA monitoringDanielle Brazel, Misako Nagasaka
Med (New York, N.Y.)|August 10, 2024
Checkmate 77T: Perioperative chemoimmunotherapy outperforms in early-stage NSCLCDanielle Brazel, Misako Nagasaka
Targeted Oncology|May 13, 2024
Divarasib in the Evolving Landscape of KRAS G12C Inhibitors for NSCLCDanielle Brazel, Misako Nagasaka
Respiratory Research|October 25, 2023
The development of amivantamab for the treatment of non-small cell lung cancerDanielle Brazel, Misako Nagasaka
Cancers|February 13, 2026
Uveal Melanoma: Biology, Prognostication, and Emerging Therapies to Outsmart an Immune-Cold MelanomaDanielle Brazel, Elizabeth Buchbinder
Lung Cancer (Auckland, N.Z.)|December 9, 2021
Spotlight on Amivantamab (JNJ-61186372) for EGFR Exon 20 Insertions Positive Non-Small Cell Lung CancerDanielle Brazel, Misako Nagasaka
Lung Cancer (Auckland, N.Z.)|May 26, 2022
Deconstructing ADAURA. It is Not Yet Time to Forgo Platinum-based Adjuvant Chemotherapy in Resected Early Stage (IB-IIIA) EGFR-mutant NSCLCDanielle Brazel, Misako Nagasaka
Lung Cancer (Auckland, N.Z.)|April 18, 2024
MARIPOSA: Can Amivantamab and Lazertinib Replace Osimertinib in the Front-Line Setting?Danielle Brazel, Misako Nagasaka
Clinical Lymphoma, Myeloma & Leukemia|April 15, 2023
SOHO State-of-the-Art Updates and Next Questions: A Modern Approach to the Systemic Treatment of Advanced CTCLDanielle Brazel, Lauren Pinter-Brown
Lung Cancer (Auckland, N.Z.)|June 29, 2023
The Additional Exclusions of <i>ROS1</i> Fusions (In Addition to <i>EGFR</i> Mutation and <i>ALK</i> Fusions) in the Cemiplimab NSCLC FDA Indication (EMPOWER-Lung 1 and -Lung 3). Catching Up with Current Scientific View of Immunotherapy in Never-Smoker Predominant Actionable Driver Mutation Positive NSCLC?Danielle Brazel, Saihong Ignatius Ou
Pageof 5